



Endometrial Cancer Commitee Agenda Chicago 03/06/2016



Ketta Lorusso, Stefano Greggi

ENDOMETRIAL CANCER: CONSERVATIVE TREATMENT


Study name	Study design	N patient enrolled/total	Contact person
ECCO TRIAL	Prospective, multicentre registry collecting data (oncological and obstetrical outcomes) on endometrial cancer patients treated conservatively according to institutional protocols	42/xx	s.greggi@istitutotumori.na.it

ENDOMETRIAL CANCER: SURGERY

Study name	Study design	N patient enrolled/total	Contact person
STATEC TRIAL	Randomized phase III trial aiming at evaluating the role of Lymphadenectomy in tailoring adjuvant treatment in EC patients	Xx/2000	Tim Mould

ECLAT-Endometrial Cancer Lymphadenectomy Trial

- histology diagnosis of EC
- FIGO IB, II (all subtypes)
- FIGO IA, G3 (type I)
- FIGO IA (Type II)
- Absence of bulky nodes



n=640

System. lymphadenectomy

- pelvic
- para-aortic

no lymphadenectomy

Primary endpoint: Overall Survival

Coordinating Investigator: Prof. Günter Emons

Type I: endometrioid, endometrioid + squamous differentiation, mucinous

Type II: serous, clear cell, carcinosarcoma

ENDOMETRIAL CANCER: ADJUVANT

Study name	Study design	N patient enrolled/total	Contact person
En 2	A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.	121/678	Mansoor Mirza
PORTEC 4A	Randomized trial of vaginal brachytherapy vs individualized treatment based on molecular – pathology analysis for high-intermediate risk endometrial carcinoma.	Xx/50	Karien Creutzberg

ENDOMETRIAL CANCER: FOLLOW UP

Study name	Study design	N patient enrolled/total	Contact person
TOTEM TRIAL	Multicentric randomized controlled clinical trial comparing two follow-up regimens with different tests intensity in EC	1440/2300	Paolo Zola

ENDOMETRIAL CANCER: ADVANCED/RECURRENT

Study name	Study design	N patient enrolled/total	Contact person
En 1	A Randomized phase II trial of first line combination chemotherapy with BIBF₁₁₂₀/placebo in patients with advanced or recurrent endometrial cancer	XX/148	Mansoor Mirza
En 3	A randomized phase II trial of Palbociclib in combination with letrozole versus letrozole for patients with estrogen receptor positive recurrent endometrial cancer.	Xx/78	Mansoor Mirza

ENDOMETRIAL CANCER: ADVANCED/RECURRENT

Study name	Study design	N patient enrolled/total	Contact person
GOG 238	Random. trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in pts with pelvic-only recurrence of EC	100/154	David Miller

ENDOMETRIAL CANCER: RARE CANCER

Study name	Study design	N patient enrolled/total	Contact person
NiCCC	Randomized phase II study on BIBF 1120 compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium	12/120	Rose Glasspool

ENDOMETRIAL CANCER: UTERINE SARCOMA

Study name	Study design	N patient enrolled/total	Contact person
GOG 277	A Randomized Phase III trial of Gemcitabine plus Docetaxel followed by Doxorubicin vs Observation for Uterus-Limited stage I, High Grade Uterine Leiomyosarcoma.	33/216	Martine Hensley
EORTC 62113-55115/ GOG UC 1306	A randomized phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUS) after stabilization or response to chemotherapy following surgery or in metastatic first line treatment	Xx/78	David Miller

ENDOMETRIAL CANCER: GTN

Study name	Study design	N patient enrolled/total	Contact person
GOG 275 (low risk GTN)	A phase III randomized trial of Pulse Actinomycin-D vs Multi-Day Methotrexate for the treatment of low risk Gestational Trophoblastic Neoplasia.	27/381	Schink
High Risk GTN	A randomized phase II trial comparing the toxicity of Paclitaxel-Etoposide (TE) alternating two weekly with Paclitaxel-Cisplatin (TP) with Etoposide and Cisplatin (EP) alternating weekly with Etoposide, Metotrexate and Dactinomycin (EMA) in GTN patients failing non platinum-based combination agent therapies.	Xx/78	Michael Seckl

NEW PROPOSAL

- Phase II trial on TRC 105 (anti-endoglin* monoclonal) +/- Bevacizumab for Patients with Metastatic Refractory Gestational Trophoblastic Neoplasia

John Lurain

- * Endoglin expression is increased in choriocarcinoma compared to normal placenta, it induces trophoblastic outgrowth and migration, and its production is stimulated by methotrexate.

Endometrial Cancer Debate

**LYMPHADENECTOMY IN
ENDOMETRIAL CANCER : STATE OF
THE ART, WHILE WAITING FOR
ONGOING CLINICAL TRIAL
RESULTS**

P. HARTER

Thank you!!!

